Compare iShares Core S&P 500 ETF (IVV) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Revvity Inc — how do they compare? iShares Core S&P 500 ETF trades at $781.97 (market cap $897.20B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: iShares Core S&P 500 ETF is far larger — about 52.8× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Revvity Inc for 12 Days on average.
| IVV | RVTY | |
|---|---|---|
Market Cap | $897.20B | $16.98B |
Volume | 4,580,672 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $157.36 |
52-Week Low | $634.93 | $82.26 |
Typical Hold Time | 46 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $777.38, down 0.41% on the day, with a bullish technical signal from moving averages and neutral oscillators. Support lies at $775 and resistance at $780. Recent news highlights strong 2026 earnings growth expectations of 35% but a projected slowdown to 15% in 2027, with valuation debates ongoing amid index concentration risks.
The outlook remains cautiously optimistic given bullish technicals and Wall Street's long-term growth projections, but risks include profit growth deceleration, high market concentration, and interest rate sensitivity. IVV offers broad market exposure, yet investors should weigh slowing corporate earnings against historical bullish seasonal trends.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
